Cargando…

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwamoto, Takayuki, Niikura, Naoki, Ogiya, Rin, Yasojima, Hiroyuki, Watanabe, Ken-ichi, Kanbayashi, Chizuko, Tsuneizumi, Michiko, Matsui, Akira, Fujisawa, Tomomi, Iwasa, Tsutomu, Shien, Tadahiko, Saji, Shigehira, Masuda, Norikazu, Iwata, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746866/ https://www.ncbi.nlm.nih.gov/pubmed/31527824 http://dx.doi.org/10.1038/s41598-019-50099-y

Ejemplares similares

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
por: Ogiya, Rin, et al.
Publicado: (2017)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study
por: Tanaka, Kiyo, et al.
Publicado: (2021)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Current approach and future perspective for ductal carcinoma in situ of the breast
por: Kanbayashi, Chizuko, et al.
Publicado: (2017)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2021)

The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2019)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer
por: Miyoshi, Yuichiro, et al.
Publicado: (2019)

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence
por: Miyoshi, Yuichiro, et al.
Publicado: (2016)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
por: Shien, Tadahiko, et al.
Publicado: (2017)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Current Status of Advance Care Planning and End‐of‐life Communication for Patients with Advanced and Metastatic Breast Cancer
por: Sagara, Yasuaki, et al.
Publicado: (2021)

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
por: Saji, Shigehira, et al.
Publicado: (2022)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
por: Masuda, Norikazu, et al.
Publicado: (2021)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient
por: Iwata, Hiroji, et al.
Publicado: (2021)

The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient
por: Iwata, Hiroji, et al.
Publicado: (2019)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
por: Masuda, Norikazu, et al.
Publicado: (2021)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)
por: Iwatani, Tsuguo, et al.
Publicado: (2021)

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
por: Shien, Tadahiko, et al.
Publicado: (2014)

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab
por: Natori, Yutaka, et al.
Publicado: (2020)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
por: Kikawa, Yuichiro, et al.
Publicado: (2022)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition
por: Yamauchi, Chikako, et al.
Publicado: (2021)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2021)

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2019)

The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition
por: Yamauchi, Chikako, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5sc3r9of9jo74v96ullt9ellqj